ANGIODYNAMICS INC (ANGO) Stock News
NASDAQ:ANGO - Nasdaq - US03475V1017 - Common Stock - Currency: USD
ANGO Latest News, Press Relases and Analysis
Smith+Nephew Stock May Gain From Strategic Deal With Standard Health
SNN teams with Standard Health to launch the United Kingdom's first orthopedic ASC, aiming to boost surgical efficiency and drive growth.
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
ECL continues to gain from its robust product portfolio and strong segmental performance.
Meta Launches Opportunity Score to All Advertisers
Opportunity Score provides AI-powered recommendations on how to improve your Meta ads.
Moelis names next CEO
Navid Mahmoodzadegan will replace Ken Moelis when the investment bank’s namesake and co-founder steps down to become executive chair Oct. 1.
NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial
Novocure's PANOVA-3 trial shows that the TTFields combo boosts survival in pancreatic cancer, hitting the primary endpoint.
What Makes AngioDynamics (ANGO) a Strong Momentum Stock: Buy Now?
Does AngioDynamics (ANGO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here's Why You Should Add HealthEquity Stock to Your Portfolio Now
HQY's sustained strength in HSAs raises optimism about the stock.
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
QDEL continues to witness growth on the back of its strong product portfolio.
3 Medical Instruments Stocks Winning Big With GenAI Amid Global Gloom
PEN, ITGR and ANGO from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and supply issues mar prospects.
Here's Why You Should Add PacBio Stock to Your Portfolio Now
PACB benefits from strong first-quarter results, product innovation, and cost cuts to offset sales cycle delays and drive 2025 growth.
Why AppLovin Stock Jumped 46% in May
The company is selling its mobile apps business for $400 million. Shares of AppLovin (NASDAQ: APP), the app-based adtech platform, were soaring last month as the company reported strong first-quarter earnings report, and benefited from a broader recovery in the market and a risk-on mentality as investors downplayed the threat from tariffs and of a slowdown in the economy. Like other growth stocks, AppLovin was hit hard by the sell-off earlier in the year, as it fell by more than 50% after popping on a strong fourth-quarter earnings report in February.
Reasons to Add Fresenius Medical Stock to Your Portfolio Now
FMS continues to gain traction on the back of acquisitions & partnerships. A tough regulatory environment raises concerns.
HealthEquity Stock Gains as Q1 Earnings Beat Estimates, Revenues Up Y/Y
HQY surpasses fiscal first-quarter revenue expectations on robust HSA growth. The company also updates its fiscal 2026 guidance.
Vivani Stock Gains After Announcing Spin-Off Plans for Cortigent Unit
VANI is set to spin off Cortigent, aiming to sharpen its focus on drug implants and unlock long-term value for both entities.
BD Stock Might See Short-term Decline After Warning on Tamponade Tubes
BDX warns of safety risks tied to its esophagogastric balloon tamponade tubes after one death and two injuries, prompting updated usage instructions for clinicians.
Are Medical Stocks Lagging AngioDynamics (ANGO) This Year?
Here is how AngioDynamics (ANGO) and Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) have performed compared to their sector so far this year.
VEEV Stock Up as Q1 Earnings & Revenues Beat Estimates, Margin Rise
Veeva Systems' fiscal first-quarter results reflect impressive performance by the Subscription services segment, along with the expansion of gross and operating margins.
Alcon Stock Rises Following the FDA Approval of TRYPTYR
FDA approves ALC's TRYPTYR, a new dry eye treatment with rapid tear production. The approval is supported by strong Phase 3 trial results.
NPCE Stock Tumbles Despite Positive One-Year Data From NAUTILUS Trial
NeuroPace reports promising one-year results from its NAUTILUS trial, showcasing the RNS System's effectiveness in treating idiopathic generalized epilepsy with sustained seizure reduction.
Reasons to Retain Veeva Systems Stock in Your Portfolio for Now
VEEV's robust product portfolio and a slew of strategic deals raise optimism about the stock.
Abbott Stock Gains Following FDA Approval of the Tendyne System
ABT wins FDA approval for its Tendyne TMVR system, offering a minimally invasive mitral valve replacement for high-risk patients with severe MAC.
BioSig Stock Surges Following Share Exchange Deal With Streamex
BSGM merges with Streamex to enter the blockchain space, aiming to revolutionize commodity tokenization and expand its footprint in digital asset markets.
PacBio Stock Slips Despite New China Distribution Deal With Haorui
PACB expands reach in China through Haorui Gene partnership, bringing HiFi sequencing to new clinical labs and boosting precision medicine access nationwide.
Reasons to Retain TransMedics Stock in Your Portfolio for Now
TMDX continues to witness growth on the back of its strength in OCS technology and the National OCS Program.
QGEN Stock Might Gain Following New Partnership With ID Solutions
QGEN teams up with ID Solutions to boost QIAcuity's reach in oncology dPCR assays, aiming to strengthen its cancer research leadership.
Is it Worth Retaining ResMed Stock in Your Portfolio Now?
RMD gains on strong mask sales and digital health growth, but faces macro headwinds and fierce competition.
AMIX Stock May Climb Following Key U.S. Patent for Nerve-Sensing Tech
Autonomix secures key U.S. patent for its groundbreaking catheter-based nerve-sensing and stimulation tech, aiming to transform treatment across major diseases
Walgreens Opens New Micro-Fulfillment Center in Brooklyn Park
WBA expands micro-fulfillment with a new facility in Brooklyn Park, MN. This will support nearly 200 Walgreens stores across the Midwest.
BAX Stock May Rise Following the Launch of FDA-Approved Hemopatch Pad
Baxter launches Hemopatch Sealing Hemostat, an FDA-approved collagen pad designed for effective hemostasis and sealing in both open and minimally invasive surgeries.
Medtronic Q4 Earnings and Revenues Top, Stock Down in Pre-market
MDT delivers strong fourth-quarter fiscal 2025 results, with significant improvements in both gross and operating margins.
Is it the Right Time to Hold STERIS Stock in Your Portfolio?
STE stays on investors' radars due to the strength of its Healthcare arm and strong rebound potential in the AST segment.
SYK Stock Likely to Rise Following FDA Clearance for OptaBlate System
Stryker secures FDA clearance for OptaBlate BVN, a groundbreaking nerve ablation system designed to treat chronic vertebrogenic lower back pain with precision and safety.
Neogen Stock Gains Following Strategic Alliance With Syngenta
NEOG inks a new strategic licensing and supply agreement with Syngenta to market and sell the latter's Talon-G and Talon Weatherblok XT rodenticides in the United States and Canada.
BD Stock May Rise Following the Launch of FACSDiscover A8 Platform
BDX unveils the BD FACSDiscover A8, a next-gen cell analyzer with spectral flow cytometry and real-time imaging, enabling deeper insights into cell function and biology.
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
ECL continues to gain from its robust product portfolio and strong segmental performance.
GEHC Stock May Rise Following the Launch of AI-Based CleaRecon DL
GE HealthCare launches CleaRecon DL, an AI-powered 3D imaging tech that enhances cone-beam CT scans by reducing artifacts, improving clarity for better interventional care.
STE Q4 Earnings Beat, Margins Expand, Stock Up in Aftermarket
STERIS' fourth-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues.
Is IDEXX Laboratories (IDXX) Outperforming Other Medical Stocks This Year?
Here is how Idexx Laboratories (IDXX) and AngioDynamics (ANGO) have performed compared to their sector so far this year.
Mentions: IDXX
Alcon Q1 Earnings Miss Estimates, Stock Down, 2025 EPS View Lowered
ALC ends the first quarter of 2025 on a disappointing note.
Prestige Consumer Stock Up 8% Since Q4 Earnings Beat, Margin Increase
PBH experiences steady international growth in the fourth quarter, banking on strong sales of the Hydralyte brand.